UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:SIK2_C11orf53 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: SIK2_C11orf53 | KinaseFusionDB ID: KFG5805 | FusionGDB2.0 ID: KFG5805 | Hgene | Tgene | Gene symbol | SIK2 | C11orf53 | Gene ID | 23235 | 341032 | |
Gene name | salt inducible kinase 2 | POU class 2 homeobox associating factor 2 | ||||||||||
Synonyms | LOH11CR1I|QIK|SIK-2|SNF1LK2 | C11orf53|OCA-T1|OCAT1 | ||||||||||
Cytomap | 11q23.1 | 11q23.1 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | serine/threonine-protein kinase SIK2SNF1-like kinase 2qin-induced kinasesalt-inducible protein kinase 2salt-inducible serine/threonine kinase 2serine/threonine-protein kinase SNF1-like kinase 2 | POU domain class 2-associating factor 2oct coactivator from tuft cells 1protein POU2AF2uncharacterized protein C11orf53 | ||||||||||
Modification date | 20240305 | 20240313 | ||||||||||
UniProtAcc | Q9H0K1 | Q8IXP5 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000304987, ENST00000533868, | ENST00000280325, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: SIK2 [Title/Abstract] AND C11orf53 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | SIK2(111491126)-C11orf53(111152123), # samples:3 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | SIK2 | GO:0006468 | protein phosphorylation | 14976552 |
Hgene | SIK2 | GO:0035556 | intracellular signal transduction | 14976552 |
Hgene | SIK2 | GO:0046777 | protein autophosphorylation | 18348280 |
Kinase Fusion gene breakpoints across SIK2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across C11orf53 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChimerDB4 | TCGA-ZJ-AAXB-01A | SIK2 | chr11 | 111491126 | C11orf53 | chr11 | 111152123 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:111491126/:111152123) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
SIK2 | C11orf53 |
FUNCTION: Serine/threonine-protein kinase that plays a role in many biological processes such as fatty acid oxidation, autophagy, immune response or glucose metabolism (PubMed:23322770, PubMed:26983400). Phosphorylates 'Ser-794' of IRS1 in insulin-stimulated adipocytes, potentially modulating the efficiency of insulin signal transduction. Inhibits CREB activity by phosphorylating and repressing TORCs, the CREB-specific coactivators (PubMed:15454081). Phosphorylates EP300 and thus inhibits its histone acetyltransferase activity (PubMed:21084751, PubMed:26983400). In turn, regulates the DNA-binding ability of several transcription factors such as PPARA or MLXIPL (PubMed:21084751, PubMed:26983400). Also plays a role in thymic T-cell development (By similarity). {ECO:0000250|UniProtKB:Q8CFH6, ECO:0000269|PubMed:15454081, ECO:0000269|PubMed:21084751, ECO:0000269|PubMed:23322770, ECO:0000269|PubMed:26983400}. | FUNCTION: Transcriptional coactivator of POU2F3 (PubMed:35576971, PubMed:36197978). This complex drives the development of tuft cells, a rare chemosensory cells that coordinate immune and neural functions within mucosal epithelial tissues (PubMed:35576971). {ECO:0000269|PubMed:35576971, ECO:0000269|PubMed:36197978}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of SIK2_C11orf53 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
SIK2 | Q9H0K1 | human | PIK3R1 | P27986 | S154 | stLYRtQsSSNLAEL | RhoGAP |
SIK2 | Q9H0K1 | human | CDK5R1 | Q15078 | S91 | ENLKKSLsCANLSTF | CDK5_activator |
SIK2 | Q9H0K1 | human | LRP6 | O75581 | S1490 | AILNPPPsPAtERsH | |
SIK2 | Q9H0K1 | human | PIK3R1 | P27986 | S541 | RISEIIDsRRRLEED | PI3K_P85_iSH2 |
SIK2 | Q9H0K1 | human | MYLK | Q15746 | S343 | PVLQKTSsSITLQAA | 23ISL |
SIK2 | Q9H0K1 | human | LRP6 | O75581 | S1420 | YVVHGPAsVPLGYVP | |
SIK2 | Q9H0K1 | human | SIK2 | Q9H0K1 | S90 | YQVMETKsMLYLVTE | Pkinase |
SIK2 | Q9H0K1 | human | CEP250 | Q9BV73 | S2392 | AGLHHsLsHsLLAVA | |
SIK2 | Q9H0K1 | human | SIK2 | Q9H0K1 | S343 | RLKSHRssFPVEQRL | |
SIK2 | Q9H0K1 | human | HDAC5 | Q9UQL6 | S259 | FPLRkTAsEPNLKVR | |
SIK2 | Q9H0K1 | human | SIK2 | Q9H0K1 | S358 | DGRQRRPstIAEQTV | |
SIK2 | Q9H0K1 | human | CEP250 | Q9BV73 | S2394 | LHHsLsHsLLAVAQA |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
SIK2 | ID | Description | 0.00e+00 |
SIK2 | GO:0043434 | response to peptide hormone | 3.70e-03 |
SIK2 | GO:0032869 | cellular response to insulin stimulus | 9.12e-03 |
SIK2 | GO:0032868 | response to insulin | 1.35e-02 |
SIK2 | GO:0071375 | cellular response to peptide hormone stimulus | 1.54e-02 |
SIK2 | GO:1901653 | cellular response to peptide | 2.14e-02 |
SIK2 | GO:1903829 | positive regulation of protein localization | 3.62e-02 |
SIK2 | GO:1905477 | positive regulation of protein localization to membrane | 3.72e-02 |
SIK2 | GO:0008286 | insulin receptor signaling pathway | 4.70e-02 |
SIK2 | GO:0030183 | B cell differentiation | 5.98e-02 |
SIK2 | GO:0090316 | positive regulation of intracellular protein transport | 5.98e-02 |
SIK2 | GO:1905475 | regulation of protein localization to membrane | 6.20e-02 |
SIK2 | GO:0032388 | positive regulation of intracellular transport | 6.20e-02 |
SIK2 | GO:0033157 | regulation of intracellular protein transport | 6.20e-02 |
SIK2 | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 6.20e-02 |
SIK2 | GO:0014820 | tonic smooth muscle contraction | 6.20e-02 |
SIK2 | GO:0021548 | pons development | 6.20e-02 |
SIK2 | GO:0032060 | bleb assembly | 6.20e-02 |
SIK2 | GO:0071476 | cellular hypotonic response | 6.20e-02 |
SIK2 | GO:1901998 | toxin transport | 6.20e-02 |
SIK2 | GO:0042113 | B cell activation | 6.20e-02 |
SIK2 | GO:1904779 | regulation of protein localization to centrosome | 6.20e-02 |
SIK2 | GO:1904953 | Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation | 6.20e-02 |
SIK2 | GO:0071900 | regulation of protein serine/threonine kinase activity | 6.20e-02 |
SIK2 | GO:0072659 | protein localization to plasma membrane | 6.20e-02 |
SIK2 | GO:0006971 | hypotonic response | 6.20e-02 |
SIK2 | GO:0098693 | regulation of synaptic vesicle cycle | 6.20e-02 |
SIK2 | GO:1900103 | positive regulation of endoplasmic reticulum unfolded protein response | 6.20e-02 |
SIK2 | GO:0021819 | layer formation in cerebral cortex | 6.20e-02 |
SIK2 | GO:0034392 | negative regulation of smooth muscle cell apoptotic process | 6.20e-02 |
SIK2 | GO:0051222 | positive regulation of protein transport | 6.20e-02 |
SIK2 | GO:0010457 | centriole-centriole cohesion | 6.20e-02 |
SIK2 | GO:0014029 | neural crest formation | 6.20e-02 |
SIK2 | GO:0009416 | response to light stimulus | 6.20e-02 |
SIK2 | GO:1904951 | positive regulation of establishment of protein localization | 6.20e-02 |
SIK2 | GO:0007158 | neuron cell-cell adhesion | 6.20e-02 |
SIK2 | GO:0010832 | negative regulation of myotube differentiation | 6.20e-02 |
SIK2 | GO:0071214 | cellular response to abiotic stimulus | 6.20e-02 |
SIK2 | GO:0104004 | cellular response to environmental stimulus | 6.20e-02 |
SIK2 | GO:0032386 | regulation of intracellular transport | 6.20e-02 |
SIK2 | GO:1904948 | midbrain dopaminergic neuron differentiation | 6.20e-02 |
SIK2 | GO:0032956 | regulation of actin cytoskeleton organization | 6.20e-02 |
SIK2 | GO:1990778 | protein localization to cell periphery | 6.20e-02 |
SIK2 | GO:0070314 | G1 to G0 transition | 6.20e-02 |
SIK2 | GO:1902074 | response to salt | 6.20e-02 |
SIK2 | GO:0071397 | cellular response to cholesterol | 6.20e-02 |
SIK2 | GO:0007213 | G protein-coupled acetylcholine receptor signaling pathway | 6.20e-02 |
SIK2 | GO:0007413 | axonal fasciculation | 6.20e-02 |
SIK2 | GO:0106030 | neuron projection fasciculation | 6.20e-02 |
SIK2 | GO:0032970 | regulation of actin filament-based process | 6.20e-02 |
Top |
Related Drugs to SIK2_C11orf53 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning SIK2-C11orf53 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to SIK2_C11orf53 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |